I am Maggie, a postdoctoral researcher working on peptide therapeutics development for the treatment of rare neurological diseases including Huntington’s Disease (HD), Spinocerebellar ataxias (SCAs), and Amyotrophic Lateral Sclerosis (ALS). I began my research journey on peptide biologics for pathogenic RNA targeting in 2018, when I started my PhD study. In 2023, my PhD supervisor Professor Edwin Chan and I co-founded a start-up biotechnology company named Rare Power with our vision to develop first-in-class innovative therapeutics for rare diseases. Some of our pipelines are currently undergoing the preclinical testing stages. In this workshop, I hope to equip myself with the latest knowledge and methodologies for analysing and optimising dosing regimens to achieve favourable pharmacokinetics and pharmacodynamics profiles for treatments.